Ranbaxy launches GSK's blockbuster drug in US

In a move that will help Ranbaxy boost its revenues from the US in the next six months, the company has launched the generic version of GlaxoSmithKline's blockbuster medicine Valtrex (valacyclovir......

Peace on patents to boost Ranbaxy

Ranbaxy Laboratories, India's largest pharmaceutical drug firm by sales, expects its recent patent litigation settlements to add significantly to its revenues as well as net profit. The numbers......

Meet Malav, the charismatic CEO of Ranbaxy

In the two years since becoming CEO, Malvinder Mohan Singh has systematically purged risk out of Ranbaxy's model. Malvinder Mohan Singh, 35, does not mind wearing a T-shirt in office - tucked in.......

Ranbaxy relents, GSK to sell Valtrex in US

Ranbaxy Laboratories has reached an agreement with GlaxoSmithKline on the litigation over the patent validity of GSK's anti-viral drug Valtrex (Valacyclovir Hydrochloride). Following this,......